Schrdinger, Inc.(NASDAQ:SDGR) 
Schrdinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in t...
Website: http://www.schrodinger.com
Founded: 1990
Full Time Employees: 392
CEO: Ramy Farid
Sector: Healthcare
Industry: Health Information Services
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
- AI-Driven Computational Drug Discovery Platform: Schrödinger provides a physics-based molecular simulation software platform used to accelerate drug discovery and materials design, combining computational chemistry with machine learning.
- Dual Revenue Model: Software + Drug Discovery Pipeline: The company generates revenue from software subscriptions/licensing and also operates an internal drug discovery effort with partnered and proprietary programs that can create longer-dated upside but adds R&D spend.
- High R&D Investment and Operating Loss Profile: Schrödinger typically reinvests heavily in R&D to expand its platform and advance its pipeline, which has historically contributed to operating losses and negative free cash flow.
- Partnerships Are Key Catalysts: Strategic collaborations with biopharma and industrial partners can drive software adoption, milestone payments, and validation of the platform’s predictive capabilities.
- Catalysts and Risks Tied to Pipeline Progress and Market Adoption: Near- to mid-term performance is often influenced by pipeline readouts, partnering activity, and enterprise software demand, while risks include long development timelines, customer budget cycles, and competitive AI drug discovery offerings.
Bull Thesis:
- Industry-Leading Computational Platform: Schrödinger possesses a highly differentiated and scientifically validated computational platform that significantly accelerates drug discovery and materials science. Its advanced physics-based modeling and machine learning capabilities are increasingly recognized as essential tools for reducing R&D costs and timelines across the pharmaceutical and biotech industries.
- Secular Shift Towards In Silico Drug Discovery: The broader pharmaceutical industry is undergoing a fundamental shift towards integrating computational methods ('in silico') earlier and more extensively in the drug discovery process. Schrödinger is exceptionally well-positioned to capitalize on this secular trend, as companies seek to improve efficiency and success rates in their pipelines.
- Robust Partnership and Internal Pipeline Model: The company's hybrid business model, combining recurring software revenue with drug discovery collaborations and an internal pipeline, offers multiple avenues for growth. Successful progression of partnered or wholly-owned drug candidates (e.g., through milestones and royalties) could unlock substantial value and further validate the power of their platform.
- Strong Recurring Software Revenue Base: A significant portion of Schrödinger's revenue comes from high-margin, recurring software subscriptions. This provides a stable and predictable revenue base that can fund ongoing R&D and sales efforts, while also demonstrating customer stickiness and the essential nature of their tools.
Bear Thesis:
- High Valuation and Path to Profitability Concerns: Despite its innovative technology, Schrödinger has historically traded at a premium valuation relative to its current revenue and profitability. The company continues to report negative free cash flow and net losses, raising questions about the timeline and path to sustainable profitability, especially in a higher interest rate environment.
- Reliance on Long-Term Drug Discovery Success: A substantial portion of Schrödinger's future value is tied to the success of its drug discovery collaborations and internal pipeline. Drug development is inherently high-risk, long-duration, and capital-intensive, meaning significant returns from these ventures may be years away and are subject to clinical trial failures.
- Competitive Landscape and Adoption Pace: While a leader, Schrödinger faces competition from other computational chemistry providers, internal R&D efforts within large pharma, and emerging AI/ML drug discovery platforms. The pace of adoption for new computational methods, while growing, can still be slower than anticipated in a traditionally conservative industry.
- Significant Cash Burn and R&D Expenses: Schrödinger continues to invest heavily in research and development to maintain its technological edge and expand its pipeline, leading to a substantial cash burn. If revenue growth from software and drug discovery milestones does not accelerate sufficiently, the company may face pressure on its balance sheet or require further capital raises.
Main Competitors:
- Dassault Systèmes ($DSY.PA) (BIOVIA (e.g., Discovery Studio, Materials Studio)), Offers a comprehensive suite of scientific software for molecular modeling, simulation, cheminformatics, and lab management. BIOVIA directly competes with Schrödinger's platform by providing tools for in silico drug discovery, materials science, and process optimization across various industries.
- Cadence Design Systems ($CDNS) (OpenEye Scientific Software (e.g., OMEGA, ROCS, VIDA)), Cadence acquired OpenEye Scientific, a direct competitor in molecular modeling and cheminformatics. OpenEye's software suite is particularly strong in ligand-based and structure-based drug design, offering alternative computational chemistry solutions to Schrödinger's platform.
- Certara, Inc. ($CERT) (Simcyp, Phoenix, D360), Certara provides a platform of biosimulation and regulatory science software, including tools for ADME/PK modeling and drug discovery. While broader in scope, it competes by offering integrated computational approaches that aim to accelerate drug development from discovery through clinical trials.
- Gaussian, Inc. (Gaussian, GaussView), Gaussian, Inc. is a leading provider of quantum chemistry software for molecular electronic structure calculations. It competes at the fundamental level of physics-based simulations that are critical for understanding molecular properties and reactions, underpinning much of drug and materials design.
Moat:
Schrödinger's competitive advantage is rooted in its highly accurate, physics-based computational platform that integrates quantum mechanics, molecular dynamics, and machine learning to accelerate drug discovery and materials design. Competition primarily comes from other software vendors offering similar computational chemistry/biology tools, broader scientific software platforms, and specialized solutions for specific R&D challenges. Key competitive factors include the accuracy and breadth of simulation capabilities, integration with experimental workflows, ease of use, and the ability to demonstrate significant acceleration and cost reduction in R&D processes. The market also sees indirect competition from AI-first drug discovery companies, some of which may develop proprietary computational platforms or utilize a combination of commercial and in-house tools.
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenues: | |||||||||||||||||||||||||
software products and services | 69,282,000 | 40,858,000 | 40,544,000 | 48,816,000 | 79,662,000 | 31,884,000 | 35,404,000 | 33,415,000 | 68,655,000 | 28,904,000 | 29,352,000 | 32,213,000 | 47,819,000 | 24,667,000 | 30,011,000 | 33,081,000 | 38,564,000 | 24,280,000 | 24,052,000 | 26,340,000 | 24,957,000 | 22,861,000 | 20,900,000 | 23,812,000 | |
drug discovery | 17,953,000 | 13,466,000 | 14,215,000 | 10,735,000 | 8,655,000 | 3,406,000 | 11,930,000 | 3,183,000 | 5,471,000 | 13,665,000 | 5,837,000 | 32,569,000 | 9,024,000 | 12,313,000 | 8,458,000 | 15,582,000 | 7,606,000 | 5,570,000 | 5,732,000 | 5,787,000 | 8,075,000 | 2,936,000 | 2,192,000 | 2,362,000 | |
total revenues | 87,235,000 | 54,324,000 | 54,759,000 | 59,551,000 | 88,317,000 | 35,290,000 | 47,334,000 | 36,598,000 | 74,126,000 | 42,569,000 | 35,189,000 | 64,782,000 | 56,843,000 | 36,980,000 | 38,469,000 | 48,663,000 | 46,170,000 | 29,850,000 | 29,784,000 | 32,127,000 | 33,032,000 | 25,797,000 | 23,092,000 | 26,174,000 | |
yoy | -1.23% | 53.94% | 15.69% | 62.72% | 19.14% | -17.10% | 34.51% | -43.51% | 30.40% | 15.11% | -8.53% | 33.12% | 23.12% | 23.89% | 29.16% | 51.47% | 39.77% | 15.71% | 28.98% | 22.74% | |||||
qoq | 60.58% | -0.79% | -8.05% | -32.57% | 150.26% | -25.44% | 29.33% | -50.63% | 74.13% | 20.97% | -45.68% | 13.97% | 53.71% | -3.87% | -20.95% | 5.40% | 54.67% | 0.22% | -7.29% | -2.74% | 28.05% | 11.71% | -11.78% | ||
cost of revenues: | |||||||||||||||||||||||||
total cost of revenues | 29,942,000 | 26,285,000 | 28,601,000 | 28,427,000 | 24,187,000 | 17,562,000 | 15,999,000 | 17,708,000 | 16,576,000 | 18,930,000 | 21,379,000 | 19,089,000 | 18,139,000 | 19,779,000 | 21,335,000 | 20,680,000 | 19,809,000 | 18,735,000 | 17,804,000 | 15,963,000 | 14,040,000 | 10,525,000 | 9,509,000 | 10,549,000 | |
gross profit | 57,293,000 | 28,039,000 | 26,158,000 | 31,124,000 | 64,130,000 | 17,728,000 | 31,335,000 | 18,890,000 | 57,550,000 | 23,639,000 | 13,810,000 | 45,693,000 | 38,704,000 | 17,201,000 | 17,134,000 | 27,983,000 | 26,361,000 | 11,115,000 | 11,980,000 | 16,164,000 | 18,992,000 | 15,272,000 | 13,583,000 | 15,625,000 | |
yoy | -10.66% | 58.16% | -16.52% | 64.76% | 11.43% | -25.01% | 126.90% | -58.66% | 48.69% | 37.43% | -19.40% | 63.29% | 46.82% | 54.75% | 43.02% | 73.12% | 38.80% | -27.22% | -11.80% | 3.45% | |||||
qoq | 104.33% | 7.19% | -15.96% | -51.47% | 261.74% | -43.42% | 65.88% | -67.18% | 143.45% | 71.17% | -69.78% | 18.06% | 125.01% | 0.39% | -38.77% | 6.15% | 137.17% | -7.22% | -25.88% | -14.89% | 24.36% | 12.43% | -13.07% | ||
gross margin % | 65.68% | 51.61% | 47.77% | 52.26% | 72.61% | 50.24% | 66.20% | 51.61% | 77.64% | 55.53% | 39.25% | 70.53% | 68.09% | 46.51% | 44.54% | 57.50% | 57.10% | 37.24% | 40.22% | 50.31% | 57.50% | 59.20% | 58.82% | 59.70% | |
operating expenses: | |||||||||||||||||||||||||
research and development | 41,399,000 | 42,757,000 | 43,138,000 | 45,844,000 | 49,362,000 | 50,977,000 | 50,835,000 | 50,611,000 | 51,487,000 | 46,833,000 | 42,705,000 | 40,741,000 | 34,542,000 | 32,885,000 | 31,123,000 | 27,822,000 | 25,145,000 | 23,219,000 | 21,092,000 | 21,448,000 | 17,319,000 | 17,019,000 | 16,657,000 | 13,700,000 | |
sales and marketing | 10,338,000 | 9,524,000 | 10,734,000 | 10,367,000 | 9,704,000 | 10,349,000 | 9,693,000 | 10,171,000 | 9,950,000 | 9,109,000 | 9,022,000 | 9,145,000 | 9,382,000 | 7,161,000 | 7,428,000 | 6,671,000 | 5,975,000 | 5,556,000 | 5,380,000 | 5,239,000 | 4,675,000 | 3,969,000 | 4,362,000 | 4,789,000 | |
general and administrative | 22,713,000 | 21,705,000 | 25,189,000 | 25,802,000 | 25,776,000 | 24,824,000 | 23,536,000 | 25,541,000 | 25,734,000 | 23,890,000 | 23,216,000 | 26,308,000 | 23,318,000 | 23,318,000 | 22,056,000 | 22,133,000 | 17,756,000 | 17,014,000 | 15,850,000 | 13,389,000 | 13,582,000 | 9,729,000 | 9,651,000 | 8,936,000 | |
total operating expenses | 74,450,000 | 73,986,000 | 79,061,000 | 82,013,000 | 84,842,000 | 86,150,000 | 84,064,000 | 86,323,000 | 87,171,000 | 79,832,000 | 74,943,000 | 76,194,000 | 67,242,000 | 63,364,000 | 60,607,000 | 56,626,000 | 48,876,000 | 45,789,000 | 42,322,000 | 40,076,000 | 35,576,000 | 30,717,000 | 30,670,000 | 27,425,000 | |
income from operations | -17,157,000 | -45,947,000 | -52,903,000 | -50,889,000 | -20,712,000 | -68,422,000 | -52,729,000 | -67,433,000 | -29,621,000 | -56,193,000 | -61,133,000 | -30,501,000 | -28,538,000 | -46,163,000 | -43,473,000 | -28,643,000 | -22,515,000 | -34,674,000 | -30,342,000 | -23,912,000 | -16,584,000 | -15,445,000 | -17,087,000 | -11,800,000 | |
yoy | -17.16% | -32.85% | 0.33% | -24.53% | -30.08% | 21.76% | -13.75% | 121.08% | 3.79% | 21.73% | 40.62% | 6.49% | 26.75% | 33.13% | 43.28% | 19.79% | 35.76% | 124.50% | 77.57% | 102.64% | |||||
qoq | -62.66% | -13.15% | 3.96% | 145.70% | -69.73% | 29.76% | -21.81% | 127.65% | -47.29% | -8.08% | 100.43% | 6.88% | -38.18% | 6.19% | 51.78% | 27.22% | -35.07% | 14.28% | 26.89% | 44.19% | 7.37% | -9.61% | 44.81% | ||
operating margin % | -19.67% | -84.58% | -96.61% | -85.45% | -23.45% | -193.88% | -111.40% | -184.25% | -39.96% | -132.00% | -173.73% | -47.08% | -50.20% | -124.83% | -113.01% | -58.86% | -48.77% | -116.16% | -101.87% | -74.43% | -50.21% | -59.87% | -74.00% | -45.08% | |
other income: | |||||||||||||||||||||||||
gain on equity investments | -109,000 | 147,322,000 | -3,000 | 11,828,000 | -48,000 | 4,156,000 | |||||||||||||||||||
change in fair value of equity investments | 46,999,000 | 9,691,000 | 4,579,000 | -13,095,000 | |||||||||||||||||||||
other income | 3,131,000 | 3,623,000 | 5,438,000 | 4,204,000 | 3,539,000 | 4,737,000 | 4,598,000 | 5,028,000 | 6,626,000 | 5,804,000 | 4,326,000 | 2,937,000 | 2,687,000 | 1,231,000 | -296,000 | ||||||||||
total other income | 50,130,000 | 13,314,000 | 10,017,000 | -8,891,000 | -18,541,000 | 30,196,000 | -1,235,000 | 13,165,000 | -1,891,000 | -8,718,000 | 44,980,000 | 185,996,000 | 1,194,000 | 6,501,000 | -4,168,000 | -5,836,000 | -7,926,000 | -341,000 | -4,561,000 | 23,463,000 | 5,223,000 | 18,696,000 | 13,085,000 | ||
income before income taxes | 32,973,000 | -32,633,000 | -42,886,000 | -59,780,000 | -39,253,000 | -38,226,000 | -53,964,000 | -54,268,000 | -31,512,000 | -64,911,000 | -16,153,000 | 155,495,000 | -27,344,000 | -39,662,000 | -47,641,000 | -34,479,000 | -30,441,000 | -35,015,000 | -34,903,000 | -449,000 | -11,361,000 | 3,251,000 | -4,002,000 | -14,180,000 | |
income tax provision | 462,000 | 162,000 | 287,000 | 28,000 | 963,000 | -90,000 | 83,000 | 456,000 | -842,000 | -2,887,000 | -20,431,000 | 26,359,000 | -136,000 | 194,000 | 33,000 | -28,000 | 274,000 | -4,000 | 67,000 | 74,000 | 225,000 | -35,000 | 64,000 | 91,000 | |
net income | 32,511,000 | -32,795,000 | -43,173,000 | -59,808,000 | -40,216,000 | -38,136,000 | -54,047,000 | -54,724,000 | -30,670,000 | -62,024,000 | 4,278,000 | 129,136,000 | -27,208,000 | -39,856,000 | -47,674,000 | -34,451,000 | -30,715,000 | -35,011,000 | -34,970,000 | -523,000 | -11,586,000 | 3,286,000 | -4,066,000 | -14,271,000 | |
yoy | -180.84% | -14.01% | -20.12% | 9.29% | 31.12% | -38.51% | -1363.37% | -142.38% | 12.72% | 55.62% | -108.97% | -474.84% | -11.42% | 13.84% | 36.33% | 6487.19% | 165.10% | -1165.46% | 760.06% | -96.34% | |||||
qoq | -199.13% | -24.04% | -27.81% | 48.72% | 5.45% | -29.44% | -1.24% | 78.43% | -50.55% | -1549.84% | -96.69% | -574.63% | -31.73% | -16.40% | 38.38% | 12.16% | -12.27% | 0.12% | 6586.42% | -95.49% | -452.59% | -180.82% | -71.51% | ||
net income margin % | 37.27% | -60.37% | -78.84% | -100.43% | -45.54% | -108.06% | -114.18% | -149.53% | -41.38% | -145.70% | 12.16% | 199.34% | -47.87% | -107.78% | -123.93% | -70.80% | -66.53% | -117.29% | -117.41% | -1.63% | -35.08% | 12.74% | -17.61% | -54.52% | |
net income per share | 0.44 | -0.45 | -0.59 | -0.82 | -0.55 | -0.52 | -0.74 | -0.76 | -0.43 | -0.86 | 0.06 | 1.81 | -0.39 | -0.56 | -0.67 | -0.48 | -0.43 | -0.49 | -0.49 | -0.18 | 0.06 | -0.05 | -0.34 | ||
weighted-average shares used for eps calculation | 73,443,298 | 73,613,090 | 73,427,635 | 73,057,916 | 72,670,295 | 72,813,006 | 72,711,685 | 72,291,134 | 71,776,301 | 71,924,451 | 71,642,722 | 71,467,097 | 71,173,419 | 71,207,992 | 71,161,892 | 71,050,432 | 70,594,950 | 70,784,184 | 70,582,062 | 70,071,625 | 60,024,658 | 66,339,570 | 63,296,366 | 40,666,970 | |
change in fair value | -22,080,000 | 25,459,000 | -5,833,000 | 8,137,000 | -8,408,000 | -14,522,000 | 40,654,000 | 35,737,000 | -1,493,000 | 5,273,000 | -15,700,000 | -6,164,000 | -7,920,000 | -627,000 | -4,918,000 | 24,824,000 | 4,750,000 | 18,233,000 | 8,359,000 | -3,079,000 | |||||
net loss attributable to noncontrolling interest | -1,000 | -3,000 | -11,000 | -2,000 | -4,000 | -326,000 | -494,000 | -447,000 | -566,000 | -716,000 | -445,000 | ||||||||||||||
net loss attributable to schrödinger common and limited common stockholders | -27,207,000 | -39,853,000 | -47,686,000 | -34,440,000 | -34,644,000 | -29,000 | -3,350,000 | -13,826,000 | |||||||||||||||||
net income attributable to noncontrolling interest | 12,000 | ||||||||||||||||||||||||
loss on equity investments | -1,781,000 | ||||||||||||||||||||||||
interest income | 328,000 | -6,000 | 286,000 | 357,000 | 420,000 | 521,000 | 463,000 | 570,000 | 699,000 | ||||||||||||||||
net income attributable to schrödinger common and limited common stockholders | -17,420,000 | -35,007,000 | -3,331,000 | 3,852,000 | |||||||||||||||||||||
total other expense | -2,380,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
current assets: | |||||||||||||||||||||||||
cash and cash equivalents | 230,517,000 | 172,120,000 | 219,901,000 | 325,997,000 | 147,326,000 | 160,416,000 | 108,109,000 | 130,236,000 | 155,315,000 | 249,378,000 | 285,963,000 | 233,206,000 | 90,474,000 | 102,817,000 | 127,319,000 | 117,257,000 | 120,267,000 | 160,879,000 | 117,699,000 | 133,122,000 | 202,296,000 | 210,490,000 | 110,380,000 | 144,749,000 | 25,986,000 |
restricted cash | 6,868,000 | 9,753,000 | 12,079,000 | 11,764,000 | 15,331,000 | 9,760,000 | 4,227,000 | 4,638,000 | 5,751,000 | 6,230,000 | 5,053,000 | 4,486,000 | 5,243,000 | 5,803,000 | 3,500,000 | 3,500,000 | 3,000,000 | 3,000,000 | 3,000,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 |
marketable securities | 164,947,000 | 219,113,000 | 230,284,000 | 174,301,000 | 204,798,000 | 228,263,000 | 269,180,000 | 300,843,000 | 307,688,000 | 246,905,000 | 262,710,000 | 294,482,000 | 360,613,000 | 370,739,000 | 382,246,000 | 408,275,000 | 456,212,000 | 436,307,000 | 495,892,000 | 515,372,000 | 440,395,000 | 388,494,000 | 173,646,000 | 143,505,000 | 59,844,000 |
accounts receivable | 83,041,000 | 29,384,000 | 10,073,000 | 20,347,000 | 235,692,000 | 13,281,000 | 11,849,000 | 19,839,000 | 65,992,000 | 19,884,000 | 9,652,000 | 46,691,000 | 55,953,000 | 23,583,000 | 18,767,000 | 29,321,000 | 31,744,000 | 11,352,000 | 21,359,000 | 11,270,000 | 31,423,000 | 12,290,000 | 13,849,000 | 16,272,000 | 18,676,000 |
unbilled and other receivables, net of allowance for unbilled receivables of 140 and 100 | 21,352,000 | 28,016,000 | 26,711,000 | ||||||||||||||||||||||
prepaid expenses | 12,540,000 | 13,336,000 | 14,947,000 | 12,562,000 | 12,205,000 | 13,136,000 | 15,493,000 | 12,349,000 | 9,926,000 | 13,111,000 | 13,999,000 | 11,396,000 | 8,569,000 | 9,104,000 | 12,062,000 | 11,542,000 | 5,030,000 | 5,509,000 | 7,293,000 | 7,954,000 | 4,409,000 | 4,449,000 | 5,294,000 | 5,881,000 | 6,468,000 |
total current assets | 519,265,000 | 471,722,000 | 513,995,000 | 570,944,000 | 634,993,000 | 456,398,000 | 449,179,000 | 493,686,000 | 567,796,000 | 547,761,000 | 591,962,000 | 603,734,000 | 533,989,000 | 524,201,000 | 556,872,000 | 586,168,000 | 625,060,000 | 622,025,000 | 649,788,000 | 675,238,000 | 682,978,000 | 621,114,000 | 307,014,000 | 312,815,000 | 118,536,000 |
property and equipment | 19,456,000 | 20,738,000 | 21,709,000 | 22,937,000 | 24,196,000 | 24,922,000 | 25,723,000 | 26,133,000 | 23,325,000 | 22,498,000 | 20,353,000 | 16,493,000 | 14,244,000 | 13,755,000 | 11,524,000 | 11,120,000 | 10,025,000 | 9,074,000 | 6,985,000 | 4,799,000 | 5,140,000 | 5,296,000 | 5,837,000 | 6,488,000 | 6,268,000 |
equity investments | 73,647,000 | 44,382,000 | 34,691,000 | 30,113,000 | 43,208,000 | 65,216,000 | 88,555,000 | 91,387,000 | 83,251,000 | 91,863,000 | 106,404,000 | 101,539,000 | 25,683,000 | 27,177,000 | 21,903,000 | 37,002,000 | 43,167,000 | 51,087,000 | 49,713,000 | 52,931,000 | 45,664,000 | 40,914,000 | 22,680,000 | 15,156,000 | 15,366,000 |
goodwill | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | 4,791,000 | |||||||||
right of use assets - operating leases | 102,736,000 | 105,107,000 | 107,346,000 | 109,661,000 | 111,883,000 | 112,816,000 | 116,525,000 | 118,578,000 | 117,778,000 | 119,822,000 | |||||||||||||||
other assets | 6,265,000 | 6,920,000 | 5,712,000 | 4,586,000 | 4,155,000 | 5,153,000 | 3,598,000 | 3,187,000 | 6,014,000 | 7,413,000 | 5,072,000 | 6,234,000 | 3,311,000 | 2,879,000 | 1,804,000 | 1,334,000 | 2,851,000 | 3,972,000 | 3,382,000 | 2,356,000 | 2,352,000 | 2,209,000 | 2,102,000 | 2,172,000 | 2,338,000 |
total assets | 726,160,000 | 653,660,000 | 688,244,000 | 743,032,000 | 823,226,000 | 669,296,000 | 688,371,000 | 737,762,000 | 802,955,000 | 794,148,000 | 841,566,000 | 838,773,000 | 688,587,000 | 661,985,000 | 687,880,000 | 719,537,000 | 756,487,000 | 762,617,000 | 717,334,000 | 744,189,000 | 746,263,000 | 680,116,000 | 349,551,000 | 349,872,000 | 155,270,000 |
liabilities and stockholders’ equity | |||||||||||||||||||||||||
current liabilities: | |||||||||||||||||||||||||
accounts payable | 11,452,000 | 9,218,000 | 8,800,000 | 11,861,000 | 10,666,000 | 11,210,000 | 8,116,000 | 9,974,000 | 16,815,000 | 10,318,000 | 12,428,000 | 11,987,000 | 9,470,000 | 10,918,000 | 5,263,000 | 9,766,000 | 8,079,000 | 8,228,000 | 5,960,000 | 7,220,000 | 8,398,000 | 4,812,000 | 5,523,000 | 6,675,000 | 3,524,000 |
accrued payroll, taxes, and benefits | 39,264,000 | 27,986,000 | 25,322,000 | 21,494,000 | 42,110,000 | 33,611,000 | 24,320,000 | 19,549,000 | 31,763,000 | 25,508,000 | 21,328,000 | 13,152,000 | 24,882,000 | 18,904,000 | 16,533,000 | 10,951,000 | 18,405,000 | 14,010,000 | 10,540,000 | 10,345,000 | 12,000,000 | 7,702,000 | 5,757,000 | 4,745,000 | |
deferred revenue | 112,853,000 | 82,283,000 | 94,543,000 | 105,458,000 | 111,944,000 | 41,773,000 | 40,799,000 | 49,497,000 | 56,231,000 | 43,313,000 | 46,674,000 | 51,578,000 | 57,931,000 | 43,920,000 | 47,440,000 | 53,771,000 | 55,368,000 | 43,874,000 | 44,069,000 | 40,759,000 | 45,403,000 | 19,067,000 | 23,138,000 | 21,710,000 | 25,054,000 |
lease liabilities - operating leases | 16,412,000 | 16,740,000 | 16,841,000 | 16,755,000 | 16,755,000 | 16,887,000 | 16,801,000 | 16,927,000 | 16,868,000 | 16,279,000 | |||||||||||||||
other accrued liabilities | 9,155,000 | 8,886,000 | 10,263,000 | 9,904,000 | 10,272,000 | 7,636,000 | 9,723,000 | 10,560,000 | 11,996,000 | 8,536,000 | 7,317,000 | 8,562,000 | 5,510,000 | 6,396,000 | 9,174,000 | 6,893,000 | 7,317,000 | 4,826,000 | 7,289,000 | 5,721,000 | 2,861,000 | 2,204,000 | 2,791,000 | 3,185,000 | 3,824,000 |
total current liabilities | 189,136,000 | 145,113,000 | 155,769,000 | 165,472,000 | 191,747,000 | 111,117,000 | 99,759,000 | 106,507,000 | 133,673,000 | 105,038,000 | 106,802,000 | 123,407,000 | 108,799,000 | 88,821,000 | 85,590,000 | 85,532,000 | 91,211,000 | 72,916,000 | 70,378,000 | 67,621,000 | 73,205,000 | 39,276,000 | 43,048,000 | 42,166,000 | 45,020,000 |
deferred revenue, long-term | 78,877,000 | 92,390,000 | 91,995,000 | 104,496,000 | 108,814,000 | 5,200,000 | 7,080,000 | 8,016,000 | 9,043,000 | 12,102,000 | 15,620,000 | 20,348,000 | 25,598,000 | 21,977,000 | 20,105,000 | 24,582,000 | 30,064,000 | 32,444,000 | 34,457,000 | 37,356,000 | 41,164,000 | 2,592,000 | 1,979,000 | 2,125,000 | |
lease liabilities - operating leases, long-term | 92,816,000 | 94,694,000 | 97,472,000 | 99,405,000 | 101,074,000 | 103,257,000 | 107,128,000 | 108,988,000 | 111,014,000 | 112,720,000 | |||||||||||||||
other liabilities, long-term | 1,278,000 | 111,000 | 136,000 | 155,000 | 146,000 | 297,000 | 424,000 | 545,000 | 667,000 | 707,000 | 600,000 | 700,000 | 800,000 | 900,000 | 1,000,000 | 1,400,000 | 300,000 | 300,000 | 300,000 | 600,000 | 654,000 | 600,000 | 600,000 | 900,000 | |
total liabilities | 362,107,000 | 332,308,000 | 345,372,000 | 369,528,000 | 401,781,000 | 219,871,000 | 214,391,000 | 224,056,000 | 254,397,000 | 230,567,000 | 230,341,000 | 248,513,000 | 240,682,000 | 198,863,000 | 194,807,000 | 188,867,000 | 199,402,000 | 182,795,000 | 111,563,000 | 112,413,000 | 122,244,000 | 49,230,000 | 53,404,000 | 54,324,000 | 57,013,000 |
commitments and contingencies | |||||||||||||||||||||||||
stockholders' equity: | |||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||
common stock | 645,000 | 645,000 | 644,000 | 642,000 | 637,000 | 637,000 | 636,000 | 635,000 | 630,000 | 628,000 | 627,000 | 623,000 | 622,000 | 620,000 | 620,000 | 620,000 | 618,000 | 617,000 | 616,000 | 613,000 | 607,000 | 563,000 | 501,000 | 501,000 | 61,000 |
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 92,000 | ||||||||||||||||||||||||
additional paid-in capital | 992,015,000 | 981,853,000 | 970,687,000 | 958,029,000 | 946,037,000 | 933,424,000 | 920,621,000 | 906,193,000 | 885,973,000 | 871,100,000 | 856,913,000 | 840,446,000 | 828,700,000 | 818,015,000 | 807,827,000 | 797,004,000 | 786,964,000 | 778,292,000 | 769,199,000 | 760,574,000 | 752,558,000 | 748,123,000 | 417,032,000 | 414,248,000 | 11,655,000 |
accumulated deficit | -628,806,000 | -661,317,000 | -628,522,000 | -585,349,000 | -525,541,000 | -485,325,000 | -447,189,000 | -393,142,000 | -338,418,000 | -307,748,000 | -245,724,000 | -250,002,000 | -379,138,000 | -351,931,000 | -312,078,000 | -264,392,000 | -229,952,000 | -199,239,000 | -164,232,000 | -129,588,000 | -129,559,000 | -118,420,000 | -122,272,000 | -118,922,000 | -105,096,000 |
accumulated other comprehensive income | 107,000 | 79,000 | -29,000 | 90,000 | 220,000 | 597,000 | -180,000 | -72,000 | -651,000 | 44,000 | 76,000 | 77,000 | 317,000 | 480,000 | 727,000 | -442,000 | 16,000 | ||||||||
total stockholders' equity | 364,053,000 | 321,352,000 | 342,872,000 | 373,504,000 | 421,445,000 | 449,425,000 | 473,980,000 | 513,706,000 | 563,581,000 | 611,225,000 | 590,260,000 | 463,122,000 | |||||||||||||
total liabilities and stockholders' equity | 726,160,000 | 653,660,000 | 688,244,000 | 743,032,000 | 823,226,000 | 669,296,000 | 688,371,000 | 737,762,000 | 794,148,000 | 841,566,000 | 838,773,000 | 661,985,000 | |||||||||||||
liabilities and stockholders' equity: | |||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net of allowance for unbilled receivables of 120 and 100 | 25,973,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at march 31, 2025 and december 31, 2024, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at march 31, 2025 and december 31, 2024, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net of allowance for unbilled receivables of 100 and 100 | 19,641,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at december 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at december 31, 2024 and december 31, 2023, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net for allowance for unbilled receivables of 130 and 100 | 31,542,000 | 40,321,000 | 25,781,000 | ||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at september 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at september 30, 2024 and december 31, 2023, respectively | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at june 30, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at june 30, 2024 and december 31, 2023, respectively | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at march 31, 2024 and december 31, 2023, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at march 31, 2024 and december 31, 2023, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net for allowance for unbilled receivables of 100 and 100 | 23,124,000 | 12,253,000 | 14,585,000 | 13,473,000 | |||||||||||||||||||||
intangible assets | 587,000 | 720,000 | 853,000 | 986,000 | |||||||||||||||||||||
stockholders’ equity: | |||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at december 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at december 31, 2023 and december 31, 2022, respectively | 92,000 | ||||||||||||||||||||||||
accumulated other comprehensive loss | 281,000 | -491,000 | -683,000 | -899,000 | -2,382,000 | -3,686,000 | -3,403,000 | -2,657,000 | |||||||||||||||||
total stockholders’ equity of schrödinger stockholders | 548,558,000 | 447,894,000 | 493,058,000 | 530,667,000 | 557,071,000 | 579,806,000 | 605,751,000 | 631,768,000 | |||||||||||||||||
noncontrolling interest | 11,000 | 12,000 | 15,000 | 3,000 | 14,000 | 16,000 | 20,000 | 8,000 | 4,000 | 8,000 | 27,000 | 31,000 | 41,000 | ||||||||||||
total stockholders’ equity | 548,558,000 | 447,905,000 | 493,073,000 | 530,670,000 | 557,085,000 | 579,822,000 | 605,771,000 | 631,776,000 | 624,019,000 | 630,886,000 | 296,147,000 | 295,548,000 | |||||||||||||
total liabilities and stockholders’ equity | 802,955,000 | 688,587,000 | 687,880,000 | 719,537,000 | 756,487,000 | 762,617,000 | 717,334,000 | 744,189,000 | |||||||||||||||||
income taxes payable | 1,084,000 | 5,134,000 | 26,318,000 | ||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at september 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at september 30, 2023 and december 31, 2022, respectively | 92,000 | ||||||||||||||||||||||||
right of use assets | 112,984,000 | 105,982,000 | 105,982,000 | 88,462,000 | 90,133,000 | 78,136,000 | 75,384,000 | 76,459,000 | 7,466,000 | 8,865,000 | 10,129,000 | 10,583,000 | 11,918,000 | 13,241,000 | 12,762,000 | ||||||||||
lease liabilities | 13,921,000 | 11,810,000 | 11,006,000 | 8,683,000 | 7,180,000 | 4,151,000 | 2,042,000 | 1,978,000 | 2,520,000 | 3,576,000 | 4,543,000 | 5,491,000 | 5,839,000 | 5,851,000 | 5,584,000 | ||||||||||
lease liabilities, long-term | 107,319,000 | 104,058,000 | 105,485,000 | 87,165,000 | 88,112,000 | 77,353,000 | 77,827,000 | 77,135,000 | 6,428,000 | 6,836,000 | 7,221,000 | 6,762,000 | 7,777,000 | 9,133,000 | |||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at june 30, 2023 and december 31, 2022, respectively | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at march 31, 2023 and december 31, 2022, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net for allowance for unbilled receivables of 100 and 30 | 13,137,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at december 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at december 31, 2022 and december 31, 2021, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net for allowance for unbilled receivables of 40 and 30 | 12,155,000 | 12,978,000 | 16,273,000 | ||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at september 30, 2022 and december 31, 2021, respectively | 92,000 | ||||||||||||||||||||||||
total stockholders' equity of schrödinger stockholders | 463,110,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at june 30, 2022 and december 31, 2021 | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at june 30, 2022 and december 31, 2021 | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at march 31, 2022 and december 31, 2021 | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at march 31, 2022 and december 31, 2021 | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net for allowance for unbilled receivables of 30 and 0 | 8,807,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at december 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at december 31, 2021 and december 31, 2020, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables, net for allowance for unbilled receivables of 20 and 0 | 4,978,000 | 4,545,000 | 7,020,000 | ||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at september 30, 2021 and december 31, 2020, respectively | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively | 92,000 | ||||||||||||||||||||||||
preferred stock, 0.01 par value. authorized 10,000,000 shares; zero shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at march 31, 2021 and december 31, 2020, respectively | 92,000 | ||||||||||||||||||||||||
unbilled and other receivables | 3,955,000 | 4,891,000 | 3,345,000 | 1,908,000 | |||||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ equity | |||||||||||||||||||||||||
convertible preferred stock: | |||||||||||||||||||||||||
series e convertible preferred stock, 0.01 par value. authorized zero and 77,150,132 shares; zero and 73,795,777 shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series d convertible preferred stock, 0.01 par value. authorized zero and 39,540,611 shares; zero and 39,540,611 shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series c convertible preferred stock, 0.01 par value. authorized zero and 47,242,235 shares; zero and 47,242,235 shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series b convertible preferred stock, 0.01 par value. authorized zero and 29,468,101 shares; zero and 29,468,101 shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series a convertible preferred stock, 0.01 par value. authorized zero and 134,704,785 shares; zero and 134,704,785 shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
total convertible preferred stock | 191,580,000 | ||||||||||||||||||||||||
stockholders’ equity | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 and 146,199,885 shares; 9,164,193 and zero shares issued and outstanding at december 31, 2020 and december 31, 2019, respectively | 92,000 | ||||||||||||||||||||||||
total stockholders’ equity (deficit) of schrödinger stockholders | 624,015,000 | 630,878,000 | 296,120,000 | 295,517,000 | |||||||||||||||||||||
total liabilities, convertible preferred stock, and stockholders’ equity | 746,263,000 | 680,116,000 | 349,551,000 | 349,872,000 | |||||||||||||||||||||
series e convertible preferred stock, 0.01 par value. authorized zero and 77,150,132 shares; zero and 73,795,777 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series d convertible preferred stock, 0.01 par value. authorized zero and 39,540,611 shares; zero and 39,540,611 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series c convertible preferred stock, 0.01 par value. authorized zero and 47,242,235 shares; zero and 47,242,235 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series b convertible preferred stock, 0.01 par value. authorized zero and 29,468,101 shares; zero and 29,468,101 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series a convertible preferred stock, 0.01 par value. authorized zero and 134,704,785 shares; zero and 134,704,785 shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
stockholders' equity | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 and 146,199,885 shares; 13,164,193 and zero shares issued and outstanding at september 30, 2020 and december 31, 2019, respectively | 132,000 | ||||||||||||||||||||||||
series e convertible preferred stock, 0.01 par value. authorized zero and 77,150,132 shares; zero and 73,795,777 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series d convertible preferred stock, 0.01 par value. authorized zero and 39,540,611 shares; zero and 39,540,611 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series c convertible preferred stock, 0.01 par value. authorized zero and 47,242,235 shares; zero and 47,242,235 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series b convertible preferred stock, 0.01 par value. authorized zero and 29,468,101 shares; zero and 29,468,101 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series a convertible preferred stock, 0.01 par value. authorized zero and 134,704,785 shares; zero and 134,704,785 shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 and 146,199,885 shares; 13,164,193 and zero shares issued and outstanding at june 30, 2020 and december 31, 2019, respectively | 132,000 | ||||||||||||||||||||||||
series e convertible preferred stock, 0.01 par value. authorized zero and 77,150,132 shares; zero and 73,795,777 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series d convertible preferred stock, 0.01 par value. authorized zero and 39,540,611 shares; zero and 39,540,611 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series c convertible preferred stock, 0.01 par value. authorized zero and 47,242,235 shares; zero and 47,242,235 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series b convertible preferred stock, 0.01 par value. authorized zero and 29,468,101 shares; zero and 29,468,101 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
series a convertible preferred stock, 0.01 par value. authorized zero and 134,704,785 shares; zero and 134,704,785 shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | |||||||||||||||||||||||||
limited common stock, 0.01 par value. authorized 100,000,000 and 146,199,885 shares; 13,164,193 and zero shares issued and outstanding at march 31, 2020 and december 31, 2019, respectively | 132,000 | ||||||||||||||||||||||||
unbilled receivables and other receivables | 7,062,000 | ||||||||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ deficit | |||||||||||||||||||||||||
accrued payroll, taxes and benefits | 7,034,000 | ||||||||||||||||||||||||
deferred revenue, long term | 2,205,000 | ||||||||||||||||||||||||
deferred rent, long term | |||||||||||||||||||||||||
lease liabilities, long term | 8,888,000 | ||||||||||||||||||||||||
other liabilities, long term | 900,000 | ||||||||||||||||||||||||
series e convertible preferred stock, 0.01 par value. authorized, 67,087,074 shares; 73,795,777 shares issued and outstanding; liquidation preference of 110,000 | 109,270,000 | ||||||||||||||||||||||||
series d convertible preferred stock, 0.01 par value. authorized, 39,540,611 shares; 39,540,611 shares issued and outstanding; liquidation preference of 22,000 | 22,000,000 | ||||||||||||||||||||||||
series c convertible preferred stock, 0.01 par value. authorized, 47,242,235 shares; 47,242,235 shares issued and outstanding, liquidation preference of 20,000 | 19,844,000 | ||||||||||||||||||||||||
series b convertible preferred stock, 0.01 par value. authorized, 29,468,101 shares; 29,468,101 shares issued and outstanding; liquidation preference of 10,000 | 9,840,000 | ||||||||||||||||||||||||
series a convertible preferred stock, 0.01 par value. authorized, 134,704,785 shares; 134,704,785 shares issued and outstanding; liquidation preference of 18,185 | 30,626,000 | ||||||||||||||||||||||||
stockholders' deficit: | |||||||||||||||||||||||||
total stockholders’ deficit of schrödinger stockholders | -93,364,000 | ||||||||||||||||||||||||
total stockholders’ deficit | -93,323,000 | ||||||||||||||||||||||||
total liabilities, convertible preferred stock, and stockholders’ deficit | 155,270,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | ||||||||||||||||||||||||
net income | -40,216,000 | -38,136,000 | -54,047,000 | -54,724,000 | -30,670,000 | -62,024,000 | 4,278,000 | 129,136,000 | ||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||
gain on equity investments | 0 | 0 | -147,322,000 | 48,000 | 0 | |||||||||||||||||||
changes in fair value of equity investments | ||||||||||||||||||||||||
depreciation and amortization | 1,437,000 | 1,465,000 | 1,531,000 | 1,589,000 | 1,764,000 | 1,558,000 | 1,401,000 | 1,436,000 | 1,354,000 | 1,273,000 | 1,165,000 | 1,760,000 | 1,142,000 | 1,107,000 | 1,126,000 | 969,000 | ||||||||
stock-based compensation | 9,950,000 | 10,846,000 | 10,627,000 | 11,574,000 | 12,479,000 | 12,398,000 | 12,808,000 | 12,218,000 | 12,534,000 | 12,654,000 | 11,773,000 | 10,880,000 | 10,205,000 | 9,864,000 | 10,427,000 | 9,134,000 | 7,456,000 | 7,652,000 | 7,016,000 | 4,366,000 | 3,003,000 | 3,038,000 | 2,729,000 | 1,775,000 |
noncash investment accretion | 480,000 | -671,000 | -815,000 | -861,000 | -1,554,000 | -2,023,000 | -2,683,000 | 534,000 | 2,393,000 | 388,000 | 1,955,000 | 287,000 | 564,000 | -288,000 | 83,000 | |||||||||
loss on disposal of property and equipment | 0 | 0 | 0 | 1,000 | 2,000 | 77,000 | 5,000 | 18,000 | 0 | -4,000 | 0 | 121,000 | 0 | 19,000 | ||||||||||
decrease in assets: | ||||||||||||||||||||||||
accounts receivable | -53,657,000 | -19,311,000 | 10,274,000 | 215,345,000 | -222,411,000 | -1,432,000 | 7,990,000 | 46,153,000 | -46,108,000 | -10,232,000 | 37,039,000 | 9,262,000 | -32,370,000 | -4,816,000 | 10,554,000 | 2,935,000 | -20,392,000 | 10,007,000 | -10,089,000 | 20,153,000 | -19,133,000 | 1,559,000 | 2,423,000 | 2,404,000 |
unbilled and other receivables | 6,664,000 | -1,305,000 | -738,000 | -6,332,000 | 11,901,000 | 8,779,000 | -14,540,000 | -2,657,000 | -10,871,000 | 2,332,000 | -1,112,000 | -336,000 | -981,000 | 823,000 | 3,295,000 | -7,390,000 | -3,829,000 | -433,000 | 2,140,000 | -3,065,000 | 888,000 | -1,546,000 | -1,028,000 | 5,154,000 |
reduction in the carrying amount of right of use assets - operating leases | 2,371,000 | 2,239,000 | 2,315,000 | 2,222,000 | 1,028,000 | 3,709,000 | 2,053,000 | 2,152,000 | 2,044,000 | |||||||||||||||
prepaid expenses and other assets | 1,451,000 | 403,000 | -3,511,000 | -788,000 | 1,832,000 | 804,000 | -3,559,000 | -2,559,000 | 4,586,000 | -1,640,000 | -5,658,000 | -5,750,000 | -230,000 | 1,882,000 | -994,000 | -7,725,000 | 1,599,000 | 1,194,000 | -365,000 | -3,549,000 | -103,000 | 737,000 | 659,000 | -1,106,000 |
increase in liabilities: | ||||||||||||||||||||||||
accounts payable | 2,210,000 | 435,000 | -3,081,000 | 1,344,000 | -677,000 | 3,499,000 | -1,791,000 | -7,150,000 | 6,579,000 | 550,000 | -2,276,000 | 2,468,000 | -1,418,000 | 5,535,000 | -4,266,000 | 1,328,000 | -182,000 | 2,260,000 | -1,259,000 | -1,230,000 | 3,628,000 | -745,000 | -111,000 | 2,110,000 |
accrued payroll, taxes, and benefits | 11,278,000 | 2,664,000 | 3,828,000 | -20,616,000 | 8,499,000 | 9,291,000 | 4,771,000 | -12,214,000 | 6,255,000 | 4,180,000 | 8,176,000 | -11,730,000 | 5,978,000 | 2,371,000 | 5,582,000 | -7,454,000 | 4,395,000 | 3,470,000 | 195,000 | -1,655,000 | 4,298,000 | 1,945,000 | 1,012,000 | -2,289,000 |
deferred revenue | 17,057,000 | -11,865,000 | -23,416,000 | -10,804,000 | 173,785,000 | -906,000 | -9,634,000 | -7,761,000 | 9,858,000 | -6,879,000 | -9,632,000 | -11,603,000 | 17,632,000 | -1,648,000 | -10,808,000 | -7,079,000 | 9,162,000 | -2,160,000 | 417,000 | -8,447,000 | 64,963,000 | -3,285,000 | 1,405,000 | -3,378,000 |
lease liabilities - operating leases | -2,206,000 | -2,879,000 | -1,847,000 | -1,669,000 | -2,315,000 | -3,785,000 | -1,986,000 | -1,967,000 | -1,117,000 | |||||||||||||||
other accrued liabilities | 1,360,000 | -1,408,000 | 367,000 | -228,000 | 2,470,000 | -2,023,000 | -1,006,000 | -1,383,000 | 3,310,000 | 391,000 | -1,286,000 | 3,502,000 | -1,172,000 | -2,986,000 | 2,223,000 | 637,000 | 1,879,000 | -2,463,000 | 1,268,000 | 2,806,000 | 712,000 | -588,000 | -696,000 | -638,000 |
net cash from operating activities | -16,093,000 | -61,873,000 | -52,198,000 | 144,063,000 | -31,113,000 | -33,256,000 | -53,723,000 | -39,276,000 | -37,255,000 | -49,941,000 | -18,443,000 | -31,094,000 | -24,942,000 | -30,363,000 | -24,656,000 | -39,722,000 | -19,738,000 | -10,638,000 | -29,372,000 | -10,921,000 | 43,618,000 | -12,032,000 | -9,051,000 | -5,778,000 |
capital expenditures | 58,000 | -509,000 | -293,000 | -558,000 | -722,000 | -1,940,000 | -1,018,000 | -3,312,000 | -2,789,000 | -6,923,000 | 234,000 | -3,276,000 | -1,191,000 | -2,880,000 | -2,211,000 | -1,036,000 | -311,000 | -2,783,000 | -2,914,000 | -513,000 | -886,000 | -325,000 | -484,000 | -843,000 |
free cash flows | -16,035,000 | -62,382,000 | -52,491,000 | 143,505,000 | -31,835,000 | -35,196,000 | -54,741,000 | -42,588,000 | -40,044,000 | -56,864,000 | -18,209,000 | -34,370,000 | -26,133,000 | -33,243,000 | -26,867,000 | -40,758,000 | -20,049,000 | -13,421,000 | -32,286,000 | -11,434,000 | 42,732,000 | -12,357,000 | -9,535,000 | -6,621,000 |
cash flows from investing activities: | ||||||||||||||||||||||||
purchases of property and equipment | -41,000 | -491,000 | -314,000 | -596,000 | -873,000 | -1,342,000 | -1,001,000 | -4,095,000 | -2,479,000 | -4,917,000 | -2,427,000 | -3,580,000 | -1,346,000 | -2,998,000 | -1,974,000 | -1,696,000 | -957,000 | -2,783,000 | -2,914,000 | -513,000 | -886,000 | -325,000 | -484,000 | -843,000 |
purchases of equity investments | -72,000 | 0 | 0 | 0 | 0 | -4,125,000 | 0 | 0 | 0 | -2,000,000 | 0 | 0 | 0 | -2,869,000 | ||||||||||
distribution from equity investment | 77,000 | 19,000 | 35,788,000 | 111,329,000 | 0 | -3,000 | 0 | 0 | 335,000 | 40,000 | 0 | 0 | ||||||||||||
proceeds from sale and disposition of equity investments | ||||||||||||||||||||||||
purchases of marketable securities | -69,252,000 | -77,645,000 | -138,506,000 | -27,556,000 | -63,873,000 | -33,953,000 | -116,387,000 | -37,126,000 | -96,111,000 | -98,799,000 | -66,891,000 | -58,823,000 | -68,097,000 | -92,160,000 | -56,147,000 | -55,068,000 | -74,293,000 | -117,784,000 | -79,054,000 | -143,671,000 | -72,852,000 | -269,122,000 | -50,585,000 | -127,109,000 |
proceeds from maturity of marketable securities | 122,966,000 | 89,595,000 | 83,219,000 | 58,784,000 | 88,293,000 | 77,201,000 | 149,966,000 | 46,300,000 | 38,899,000 | 116,900,000 | 100,773,000 | 127,401,000 | 81,000,000 | 103,001,000 | 81,215,000 | 99,495,000 | 174,943,000 | 98,145,000 | 66,500,000 | |||||
net cash from investing activities | 71,408,000 | 11,459,000 | -55,601,000 | 30,632,000 | 23,475,000 | 90,704,000 | 29,578,000 | 5,079,000 | -59,614,000 | 13,203,000 | 67,243,000 | 172,202,000 | 11,557,000 | 7,840,000 | 34,322,000 | 36,304,000 | -22,091,000 | 52,376,000 | 14,812,000 | -61,909,000 | -53,238,000 | -215,983,000 | -24,587,000 | -87,913,000 |
cash flows from financing activities: | ||||||||||||||||||||||||
proceeds from issuances of common stock upon stock option exercises | 212,000 | 321,000 | ||||||||||||||||||||||
proceeds from issuance of common stock in atm offering | ||||||||||||||||||||||||
payment of offering costs | 0 | -199,000 | ||||||||||||||||||||||
principal payments on finance leases | -15,000 | -14,000 | -15,000 | -14,000 | -15,000 | -14,000 | -15,000 | -14,000 | -14,000 | |||||||||||||||
net cash from financing activities | 197,000 | 307,000 | 2,018,000 | 409,000 | 119,000 | 392,000 | 1,607,000 | 8,005,000 | 2,327,000 | 1,330,000 | 4,524,000 | 867,000 | 482,000 | 324,000 | 396,000 | 908,000 | 1,217,000 | 1,442,000 | 1,637,000 | 3,656,000 | 1,426,000 | 328,125,000 | -731,000 | 212,454,000 |
net increase in cash and cash equivalents and restricted cash | 55,512,000 | -50,107,000 | -105,781,000 | 175,104,000 | -7,519,000 | 57,840,000 | -22,538,000 | -26,192,000 | -94,542,000 | -35,408,000 | 53,324,000 | 141,975,000 | -40,612,000 | 43,180,000 | -12,923,000 | -69,174,000 | -8,194,000 | 100,110,000 | -34,369,000 | 118,763,000 | ||||
cash and cash equivalents and restricted cash, beginning of year | ||||||||||||||||||||||||
cash and cash equivalents and restricted cash, end of year | ||||||||||||||||||||||||
supplemental disclosure of non-cash investing and financing activities | ||||||||||||||||||||||||
purchases of property and equipment in accounts payable | 24,000 | -18,000 | 21,000 | 13,000 | 132,000 | -405,000 | -66,000 | 501,000 | -82,000 | -2,661,000 | 2,717,000 | 218,000 | -29,000 | 118,000 | -237,000 | 317,000 | 646,000 | |||||||
purchases of property and equipment in accrued liabilities | 75,000 | 25,000 | 19,000 | -193,000 | 49,000 | 282,000 | -228,000 | 655,000 | -56,000 | 86,000 | 184,000 | 343,000 | ||||||||||||
acquisition of right of use assets - operating leases, contingency resolution | 0 | 0 | 0 | 2,848,000 | 0 | |||||||||||||||||||
acquisition of right of use assets in exchange for lease liabilities - operating leases | ||||||||||||||||||||||||
acquisition of right of use assets in exchange for lease liabilities - finance leases | 0 | |||||||||||||||||||||||
net loss | -32,795,000 | -43,173,000 | -59,808,000 | -27,208,000 | -39,856,000 | -47,674,000 | -34,451,000 | -30,715,000 | -35,011,000 | -34,970,000 | -523,000 | -11,586,000 | 3,286,000 | -4,066,000 | -14,271,000 | |||||||||
adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||||||||||||||
loss on equity investments | 0 | 3,000 | 0 | 0 | 0 | 1,781,000 | ||||||||||||||||||
fair value adjustments of equity investments | -9,691,000 | -4,579,000 | 13,095,000 | |||||||||||||||||||||
proceeds from disposition and sale of equity investments | 0 | |||||||||||||||||||||||
cash and cash equivalents and restricted cash, beginning of period | 0 | 0 | 162,657,000 | 0 | 0 | 161,066,000 | 0 | 0 | 95,717,000 | 0 | 0 | 123,267,000 | 0 | 0 | 202,796,000 | 0 | 0 | 26,486,000 | ||||||
cash and cash equivalents and restricted cash, end of period | -50,107,000 | -105,781,000 | 337,761,000 | 57,840,000 | -22,538,000 | 134,874,000 | -35,408,000 | 53,324,000 | 237,692,000 | -22,199,000 | 10,062,000 | 120,757,000 | 43,180,000 | -12,923,000 | 133,622,000 | 100,110,000 | -34,369,000 | 145,249,000 | ||||||
supplemental disclosure of cash flow and noncash information | ||||||||||||||||||||||||
cash paid for income taxes | 285,000 | 226,000 | 139,000 | 233,000 | 408,000 | 259,000 | 180,000 | 634,000 | 1,276,000 | 832,000 | 86,000 | 325,000 | 291,000 | 134,000 | 37,000 | 212,000 | 12,000 | 105,000 | 119,000 | 156,000 | 76,000 | 85,000 | 64,000 | |
issuances of common stock upon stock option exercises | 423,000 | 134,000 | 406,000 | 558,000 | 392,000 | 2,341,000 | 1,534,000 | 4,698,000 | 867,000 | 482,000 | 324,000 | 396,000 | 908,000 | 1,442,000 | 1,612,000 | 3,656,000 | ||||||||
issuance of common stock in atm offering | ||||||||||||||||||||||||
changes in fair value | ||||||||||||||||||||||||
noncash investment amortization | -2,799,000 | -964,000 | -1,473,000 | 383,000 | 215,000 | 1,504,000 | ||||||||||||||||||
decrease in assets, net of acquisition: | ||||||||||||||||||||||||
increase in liabilities, net of acquisition: | ||||||||||||||||||||||||
acquisition, net of acquired cash | 0 | 0 | 0 | -6,427,000 | ||||||||||||||||||||
acquisition of right of use assets - operating leases | ||||||||||||||||||||||||
acquisition of lease liabilities - operating leases | ||||||||||||||||||||||||
fair value adjustments | -25,459,000 | 5,833,000 | -8,137,000 | 8,408,000 | 14,522,000 | -40,654,000 | -35,737,000 | 1,493,000 | -5,273,000 | 15,700,000 | 6,164,000 | 7,920,000 | 627,000 | 4,918,000 | -24,824,000 | -4,750,000 | -18,233,000 | -8,359,000 | 3,079,000 | |||||
income taxes payable | -4,050,000 | -21,184,000 | 25,963,000 | |||||||||||||||||||||
issuance of common stock upon atm offering | 0 | 1,064,000 | 7,627,000 | |||||||||||||||||||||
accrued offering costs | 786,000 | |||||||||||||||||||||||
noncash revenue from equity investments | -48,000 | -48,000 | -6,000 | -5,000 | -55,000 | -173,000 | -123,000 | -46,000 | ||||||||||||||||
noncash research and development expenses | 0 | 0 | 313,000 | 498,000 | 443,000 | 547,000 | 712,000 | 435,000 | ||||||||||||||||
proceeds from sale of equity investments | 0 | 0 | 0 | 15,735,000 | ||||||||||||||||||||
contribution by noncontrolling interest | 0 | 0 | ||||||||||||||||||||||
acquisition of right of use assets - operating leases in exchange for lease liabilities - operating leases | ||||||||||||||||||||||||
noncash (accretion) investment amortization | ||||||||||||||||||||||||
reduction in the carrying amount of right of use assets | 2,475,000 | 1,672,000 | 1,919,000 | 1,221,000 | 1,075,000 | 2,061,000 | 1,399,000 | 1,264,000 | 1,385,000 | 1,335,000 | 1,323,000 | 1,299,000 | ||||||||||||
lease liabilities | -961,000 | -623,000 | 980,000 | 556,000 | -125,000 | 489,000 | 756,000 | -889,000 | -1,464,000 | -1,352,000 | -1,420,000 | -1,363,000 | -1,368,000 | -1,266,000 | ||||||||||
acquisition of right to use assets, contingency resolution | -1,306,000 | 1,820,000 | 0 | 0 | 0 | 1,513,000 | ||||||||||||||||||
acquisition of right of use assets in exchange for lease liabilities | ||||||||||||||||||||||||
gain on disposal of property and equipment | ||||||||||||||||||||||||
acquisition of right of use assets | 0 | 13,621,000 | 1,146,000 | |||||||||||||||||||||
acquisition of lease liabilities | 19,663,000 | 0 | 13,621,000 | 1,146,000 | ||||||||||||||||||||
issuances of common stock upon initial public offering | 0 | 0 | -786,000 | 212,277,000 | ||||||||||||||||||||
issuances of common stock upon follow-on public offering | -10,000 | |||||||||||||||||||||||
acquisitions of right of use assets | ||||||||||||||||||||||||
reclassification of deferred financing costs to additional paid-in capital | ||||||||||||||||||||||||
net decrease in cash and cash equivalents and restricted cash | -2,510,000 | |||||||||||||||||||||||
adjustments to reconcile net loss to net cash from | ||||||||||||||||||||||||
operating activities: | ||||||||||||||||||||||||
gain on lease termination | ||||||||||||||||||||||||
depreciation | 652,000 | 581,000 | 727,000 | 887,000 | 1,010,000 | 890,000 | 881,000 | 877,000 | ||||||||||||||||
proceeds from sale and maturity of marketable securities | 20,500,000 | 53,464,000 | 21,900,000 | 42,908,000 | ||||||||||||||||||||
issuances of series e preferred stock | ||||||||||||||||||||||||
issuances of common stock upon stock option exercise | 1,436,000 | 2,515,000 | 55,000 | 177,000 | ||||||||||||||||||||
deferred offering costs | ||||||||||||||||||||||||
accrued deferred offering costs | ||||||||||||||||||||||||
acquisitions of right of use assets in exchange for lease obligations | 0 | 931,000 | 0 | 0 | 1,778,000 | |||||||||||||||||||
right of use assets recognized on adoption | ||||||||||||||||||||||||
reclassification of deferred financing costs to additional paid in capital | ||||||||||||||||||||||||
payment of deferred offering costs | ||||||||||||||||||||||||
reclass of deferred financing costs to additional paid in capital | 0 | |||||||||||||||||||||||
noncash rent expense | ||||||||||||||||||||||||
other receivables | ||||||||||||||||||||||||
reduction in the carrying amount of right of use asset | ||||||||||||||||||||||||
issuances of common stock | ||||||||||||||||||||||||
noncash operating activities: | ||||||||||||||||||||||||
acquisition of right of use assets in exchange for lease obligations |